CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 10% – What’s Next?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) traded up 10% on Monday . The company traded as high as $2.56 and last traded at $2.52. 24,137 shares changed hands during trading, a decline of 35% from the average session volume of 36,980 shares. The stock had previously closed at $2.29.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, CNS Pharmaceuticals has an average rating of “Hold” and an average target price of $20.00.

CNS Pharmaceuticals Stock Up 10.0%

The firm has a fifty day moving average price of $4.18 and a two-hundred day moving average price of $6.28. The stock has a market capitalization of $1.56 million, a P/E ratio of -0.08 and a beta of 2.70.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Armistice Capital LLC bought a new position in shares of CNS Pharmaceuticals in the second quarter worth approximately $335,000. Ikarian Capital LLC bought a new stake in shares of CNS Pharmaceuticals during the fourth quarter valued at approximately $241,000. Finally, Boothbay Fund Management LLC purchased a new position in CNS Pharmaceuticals in the 4th quarter worth approximately $71,000. 14.02% of the stock is owned by hedge funds and other institutional investors.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.